Welcome to LookChem.com Sign In|Join Free

CAS

  • or

121055-07-0

Post Buying Request

121055-07-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

121055-07-0 Usage

General Description

(+)-endo-2-Aminonorbornane is a chemical compound that belongs to the class of amines. It has a bicyclo[2.2.1]heptane or norbornane structure with an amino group attached to one of the carbon atoms. (+)-endo-2-Aminonorbornane exists in two enantiomeric forms, with the (+)-endo-2-Aminonorbornane being the specific stereoisomer. It is used as a chiral auxiliary in organic synthesis to facilitate the preparation of enantiomerically pure compounds. The compound has also been studied for its potential biological activities, including its use as a ligand in the development of pharmaceuticals and agrochemicals. Overall, (+)-endo-2-Aminonorbornane is a versatile compound with applications in both chemical synthesis and medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 121055-07-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,1,0,5 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 121055-07:
(8*1)+(7*2)+(6*1)+(5*0)+(4*5)+(3*5)+(2*0)+(1*7)=70
70 % 10 = 0
So 121055-07-0 is a valid CAS Registry Number.

121055-07-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (+)-endo-2-Aminonorbornane

1.2 Other means of identification

Product number -
Other names exo-2-aminonorbornane

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:121055-07-0 SDS

121055-07-0Relevant articles and documents

Potential Synthetic Adaptogens: V. Synthesis of Cage Monoamines by the Schwenk–Papa Reaction

Brunilin, R. V.,Mkrtchyan, A. S.,Nawrozkij, M. B.,Novakov, I. A.,Vernigora, A. A.,Voloboev, S. N.,Vostrikova, O. V.

, p. 1742 - 1748 (2020/01/11)

The reduction of cage ketoximes under Schwenk–Papa reaction conditions was studied to establish that the d,l, d- and l-camphor oximes are smoothly reduced to the corresponding amines in high yields. At the same time, d,l-norcamphor and adamantan-2-one oximes undergo partial catalytic deoximation to form a mixture of the corresponding amines and alcohols.

Iridium-catalyzed intermolecular hydroamination of unactivated aliphatic alkenes with amides and sulfonamides

Sevov, Christo S.,Zhou, Jianrong,Hartwig, John F.

supporting information; experimental part, p. 11960 - 11963 (2012/09/08)

The intermolecular addition of N-H bonds to unactivated alkenes remains a challenging, but desirable, strategy for the synthesis of N-alkylamines. We report the intermolecular amination of unactivated α-olefins and bicycloalkenes with arylamides and sulfonamides to generate synthetically useful protected amine products in high yield. Mechanistic studies on this rare catalytic reaction revealed a resting state that is the product of N-H bond oxidative addition and coordination of the amide. Rapid, reversible dissociation of the amide precedes reaction with the alkene, but an intramolecular, kinetically significant rearrangement of the species occurs before this reaction with alkene.

ISOXAZOLES AND THEIR USE IN THE TREATMENT OF ISCHEMIC DISEASES

-

Page 27, (2010/02/06)

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of neurological, neurodegenerative, ischemic and inflammatory disorders. Accordingly, the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of neurological, neurodegenerative, ischemic and inflammatory disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 121055-07-0